Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

539 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gastric-Type Adenocarcinoma of the Uterine Cervix Associated with Poor Response to Definitive Radiotherapy.
Kuruma A, Kodama M, Hori Y, Sato K, Fujii M, Isohashi F, Miyoshi A, Mabuchi S, Setoguchi A, Shimura H, Goto T, Toda A, Nakagawa S, Kinose Y, Takiuchi T, Kobayashi E, Hashimoto K, Ueda Y, Sawada K, Morii E, Kimura T. Kuruma A, et al. Among authors: shimura h. Cancers (Basel). 2022 Dec 28;15(1):170. doi: 10.3390/cancers15010170. Cancers (Basel). 2022. PMID: 36612167 Free PMC article.
Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1.
Nakae A, Kodama M, Okamoto T, Tokunaga M, Shimura H, Hashimoto K, Sawada K, Kodama T, Copeland NG, Jenkins NA, Kimura T. Nakae A, et al. Among authors: shimura h. Biochem Biophys Res Commun. 2021 May 7;552:120-127. doi: 10.1016/j.bbrc.2021.03.049. Epub 2021 Mar 18. Biochem Biophys Res Commun. 2021. PMID: 33744759
Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study.
Nishikawa N, Hatano T, Nishioka K, Ueno SI, Saiki S, Nakamura R, Yoritaka A, Ogawa T, Shimo Y, Sako W, Shimura H, Furukawa Y, Kamei T, Ishida T, Hattori N; J-SILVER study group. Nishikawa N, et al. Among authors: shimura h. J Neurol Sci. 2024 May 17;461:123051. doi: 10.1016/j.jns.2024.123051. Online ahead of print. J Neurol Sci. 2024. PMID: 38788287 Free article.
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
RECAP study group; Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Wakui H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. RECAP study group, et al. Among authors: shimura h. Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15652. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38764356
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y, Kawanami D. Muta Y, et al. Among authors: shimura h. Front Pharmacol. 2024 Mar 27;15:1358573. doi: 10.3389/fphar.2024.1358573. eCollection 2024. Front Pharmacol. 2024. PMID: 38601470 Free PMC article.
539 results